BlackRock Fund Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

BlackRock Fund Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$128M	Buy	7,891,641 +838,740	+12%	+$15.2M	0.02%	1013
2016 Q3	$128M	Buy	7,052,901 +374,765	+6%	+$7.32M	0.03%	893
2016 Q2	$110M	Buy	6,678,136 +3,740,449	+127%	+$60.5M	0.02%	898
2016 Q1	$48.7M	Buy	2,937,687 +208,391	+8%	+$3.65M	0.01%	1475
2015 Q4	$59.1M	Sell	2,729,296 -310,832	-10%	-$6.05M	0.01%	1363
2015 Q3	$60.3M	Buy	3,040,128 +1,010,150	+50%	+$31.9M	0.02%	1292
2015 Q2	$70.5M	Buy	+2,029,978	New	+$61.9M	0.02%	1275
2014 Q3	–	Sell	-2,303,695	Closed	-$36.4M	–	3908
2014 Q2	$36.4M	Sell	2,303,695 -33,043	-1%	-$472K	0.01%	1617
2014 Q1	$35.3M	Buy	2,336,738 +177,664	+8%	+$2.01M	0.01%	1642
2013 Q4	$16.5M	Buy	2,159,074 +699,267	+48%	+$3.77M	0.01%	2097
2013 Q3	$4.89M	Buy	1,459,807 +154,431	+12%	+$407K	﹤0.01%	2824
2013 Q2	$3.21M	Buy	+1,305,376	New	+$3.13M	﹤0.01%	2951

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors's HZNP Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 12% in Q4 2016, buying an estimated $15.2M and bringing the position to 7,891,641 shares worth $128M. The position accounts for 0.02% of the portfolio, ranked #1013.

BlackRock Fund Advisors first reported a position in HZNP in Q2 2013 and has held it in 12 quarters since. The position peaked at $128M in Q3 2016. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

BlackRock Fund Advisors held 7,891,641 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $128M as of Q4 2016.
BlackRock Fund Advisors bought 838,740 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $15.2M.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.02% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1013 holding.
BlackRock Fund Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and has held it in 12 quarters since.
BlackRock Fund Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $128M in Q3 2016.
234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.